Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2006

View Archived Issues

Hunter's syndrome patients benefit from idursulfase infusions

Defibrotide demonstrates anticancer potential

Preclinical insulinotropic efficacy and stability of novel GLP-1 and GIP analogues reported

Crucell and VRC begin phase I study of Ebola vaccine

Pfizer acquires license to gene RTP-801 with relevance to AMD

Kalypsys advancing KD-3010 for metabolic disorders

MacuSight studies proprietary formulation of sirolimus in diabetic macular edema

VQD-001 studied in phase I/II solid tumor study

AN-2690 demonstrates efficacy in phase II onychomycosis study

QR-333 administered safely in subjects with diabetic peripheral neuropathy

Contrave achieves greater weight loss than placebo with no sign of plateau

Satraplatin meets progression-free survival endpoint in SPARC trial

InterMune files to begin phase I program for HCV protease inhibitor ITMN-191

Millennium to acquire AnorMED

Pericor Science makes advance in thrombin inhibitor research

Elan and Transition Therapeutics collaborate on AZD-103 for Alzheimer's

ACV-1 enters phase II for neuropathic pain

Survival benefit for AS-1404 in NSCLC

First sales for seasonal influenza vaccine Anflu in China

R&D highlights from the UBS Global Life Sciences Conference in New York: NeurogesX

Rasilez filed for European approval

Abraxane submitted for breast cancer in Europe

LN-1-255: a novel beta-lactamase inhibitor

Preclinical update on DC-159a: a promising fluoroquinolone for treatment of respiratory infections

New PDK1 inhibitors from Berlex described

L-90268: a novel prostanoid EP4 receptor agonist with ocular hypotensive activity

New NK2 receptor antagonist with potential use in IBS

New therapeutic agents for HIV infection disclosed in recent Tibotec and Shionogi patents

Recent patents report novel analgesic agents

Novel agents for inflammatory disorders disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...